Supplementary Figure 1 from Multiomic Factor Analysis for Pathologic Complete Response after Pembrolizumab + Trastuzumab + Pertuzumab in HER2-Enriched Early Breast Cancer: WSG-Keyriched-1 Trial

Supplementary Figure 1. Mean sTIL levels at baseline (A) and week 3 (B) by pCR status. At week 3, sTILs could not be measured due to a low cellularity in 2 patients with non-pCR and in 10 patients with pCR; measurements were not performed in further two patients (one with and one without pCR).